Beranda › Migrain › Florida › Tampa
Uji klinis Migrain di Tampa, FL
6 studi untuk Migrain mencari peserta di lokasi sekitar Tampa (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Study of EVO756 in Adults With Migraine
Menerima pesertaFase 2
- Vantage Clinical Trials, Tampa
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Menerima pesertaFase 3
- Santos Research Center, CORP, Tampa
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Menerima pesertaFase 3
- University of South Florida- Neuroscience Institute /ID# 229324, Tampa
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
Menerima pesertaFase 3
- University of South Florida, Tampa
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
Menerima pesertaFase 2
- Santos Research Center, Corp - Tampa, Tampa
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
Menerima pesertaFase 4
- Upsher-Smith Clinical Trial Site #14, Tampa
Uji klinis Migrain di kota lain
- Cincinnati, OH11 studi
- Austin, TX8 studi
- Miami, FL8 studi
- Philadelphia, PA8 studi
- Concord, CA8 studi
- Amherst, NY7 studi
- Omaha, NE7 studi
- Houston, TX7 studi
- Washington, DC7 studi
- Aurora, CO6 studi
- Stamford, CT6 studi
- San Diego, CA6 studi
Studi lain di Tampa
- Kanker Paru Non-Sel Kecil51 studi
- Kanker Payudara43 studi
- Kanker (semua jenis)39 studi
- Kanker Kolorektal33 studi
- Kanker Metastatik29 studi
- Kanker Paru29 studi
- Leukemia Mieloid Akut29 studi
- Kanker Pankreas26 studi
- Kanker Ovarium21 studi
- Sindrom Mielodisplastik19 studi
- Melanoma19 studi
- Gagal Jantung18 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.